Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 160,347 shares, a growth of 22.0% from the December 31st total of 131,425 shares. Based on an average daily trading volume, of 101,779 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.6% of the company’s shares are short sold. Currently, 1.6% of the company’s shares are short sold. Based on an average daily trading volume, of 101,779 shares, the days-to-cover ratio is currently 1.6 days.

Cocrystal Pharma Trading Up 2.4%

Shares of NASDAQ COCP traded up $0.02 during midday trading on Wednesday, reaching $0.98. The company’s stock had a trading volume of 5,874 shares, compared to its average volume of 84,877. The stock has a 50 day simple moving average of $1.03 and a 200-day simple moving average of $1.23. The stock has a market capitalization of $13.56 million, a price-to-earnings ratio of -1.05 and a beta of 1.20. Cocrystal Pharma has a fifty-two week low of $0.90 and a fifty-two week high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last announced its earnings results on Friday, November 14th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. As a group, equities analysts anticipate that Cocrystal Pharma will post -1.85 EPS for the current year.

Insider Transactions at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was bought at an average cost of $0.95 per share, for a total transaction of $47,500.00. Following the transaction, the director owned 1,838,551 shares of the company’s stock, valued at $1,746,623.45. This represents a 2.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 159,000 shares of company stock worth $152,710 in the last quarter. 28.14% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.